Tom Gallen
Managing Editor, Europe
Tom reports and edits European consumer healthcare industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switch.
Latest From Tom Gallen
ASA Finds 'Irresponsible' Weight Loss Ad Difficult To Stomach
Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible."
DSM Overcomes Supply Chain Challenges To Post First-Half Sales Gain
Heerlen, Netherlands-based DSM posted a double-digit rise in sales at its Health, Nutrition and Care operation in the first half despite facing a "continuous battle" to place and receive deliveries.
UK Product Approvals: J&J Expands Sudafed And Nicorette Offerings
The UK's MHRA has approved the Rx-to-OTC switch of J&J's Sudafed Plus nasal spray (xylometazoline hydrochloride/dexpanthenol) and given the green light for the company to add new pack sizes to its Nicorette QuickMist and QuickMist Smart Track products.
New Iron Source Granted EU Novel Food Approval
Ireland's Nemysis Limited has secured authorization from the European Commission to market in the EU a novel form of iron in supplements for both adults and children.
Dermapharm Expands Natural Offering With France's Arkopharma
Germany's Dermapharm will pay €450m to acquire herbal specialist Arkopharma to expand its footprint in Europe's consumer health market in countries such as France, Spain and Italy.
People On The Move: HRA Pharma, Hofseth BioCare, UK CHM
A round-up of the latest people moves in Europe's health and wellness markets: HRA Pharma's CEO David Wright steps down; Hofseth BioCare promotes Ødegård to lead the company; and the UK's Commission on Human Medicines appoints nine new members.